Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Lung Cancer

  Free Subscription


Articles published in Eur J Cancer

Retrieve available abstracts of 154 articles:
HTML format



Single Articles


    April 2024
  1. KATSUMATA S, Shimokawa M, Hamada A, Haratake N, et al
    Impact of central nervous system metastasis after complete resection of lung adenocarcinomas harboring common EGFR mutation - A real-world database study in Japan: The CReGYT-01 EGFR study.
    Eur J Cancer. 2024;201:113951.
    PubMed     Abstract available


    March 2024
  2. LEONETTI A, Perrone F, Puntoni M, Maglietta G, et al
    Real-world outcomes of Italian patients with advanced non-squamous lung cancer treated with first-line pembrolizumab plus platinum-pemetrexed.
    Eur J Cancer. 2024;202:114006.
    PubMed     Abstract available


  3. CATOZZI S, Assaad S, Delrieu L, Favier B, et al
    Early morning immune checkpoint blockade and overall survival of patients with metastatic cancer: An In-depth chronotherapeutic study.
    Eur J Cancer. 2024;199:113571.
    PubMed     Abstract available


  4. BRAHMER JR, Long GV, Hamid O, Garon EB, et al
    Safety profile of pembrolizumab monotherapy based on an aggregate safety evaluation of 8937 patients.
    Eur J Cancer. 2024;199:113530.
    PubMed     Abstract available


  5. WANG M, Wang T, Shan J, Sun Y, et al
    Alectinib induced vitiligo with rapid re-pigmentation.
    Eur J Cancer. 2024;200:113582.
    PubMed    


  6. GOMEZ-RANDULFE I, Leporati R, Gupta B, Liu S, et al
    Recent advances and future strategies in first-line treatment of ES-SCLC.
    Eur J Cancer. 2024;200:113581.
    PubMed     Abstract available


    February 2024
  7. STRATMANN JA, Althoff FC, Doebel P, Rauh J, et al
    Sotorasib in KRAS G12C-mutated non-small cell lung cancer: A multicenter real-world experience from the compassionate use program in Germany.
    Eur J Cancer. 2024;201:113911.
    PubMed     Abstract available


  8. MARK M, Froesch P, Gysel K, Rothschild SI, et al
    First-line durvalumab in patients with PD-L1 positive, advanced non-small cell lung cancer (NSCLC) with a performance status of 2 (PS2). Primary analysis of the multicenter, single-arm phase II trial SAKK 19/17.
    Eur J Cancer. 2024;200:113600.
    PubMed     Abstract available


  9. EBSTEIN E, Brocard P, Soussi G, Khoury R, et al
    Burden of comorbidities: Osteoporotic vertebral fracture during non-small cell lung cancer - the BONE study.
    Eur J Cancer. 2024;200:113604.
    PubMed     Abstract available


  10. CHIANG Y, Lu LF, Tsai CL, Tsai YC, et al
    C-C chemokine receptor 4 (CCR4)-positive regulatory T cells interact with tumor-associated macrophages to facilitate metastatic potential after radiation.
    Eur J Cancer. 2024;198:113521.
    PubMed     Abstract available


    January 2024
  11. BLASI M, Kuon J, Luders H, Misch D, et al
    First-line immunotherapy for lung cancer with MET exon 14 skipping and the relevance of TP53 mutations.
    Eur J Cancer. 2024;199:113556.
    PubMed     Abstract available


  12. OLIVIER T, Addeo A
    Shrinking sample sizes in lung cancer trials: Various explanations, open questions.
    Eur J Cancer. 2024;199:113527.
    PubMed    


  13. JANKU F, Kim TM, Iyer G, Spreafico A, et al
    First-in-human study of naporafenib (LXH254) with or without spartalizumab in adult patients with advanced solid tumors harboring MAPK signaling pathway alterations.
    Eur J Cancer. 2024;196:113458.
    PubMed     Abstract available


  14. BELDERBOS RA, Corneth OBJ, Dumoulin D, Hendriks RW, et al
    Atypical B cells (CD21-CD27-IgD-) correlate with lack of response to checkpoint inhibitor therapy in NSCLC.
    Eur J Cancer. 2024;196:113428.
    PubMed     Abstract available


  15. DE MIGUEL-PEREZ D, Pickering EM, Malapelle U, Grier W, et al
    Genomic profiling of tissue and blood predicts survival outcomes in patients with resected pleural mesothelioma.
    Eur J Cancer. 2024;196:113457.
    PubMed     Abstract available


  16. SCHALLENBERG S, Dernbach G, Dragomir MP, Schlachtenberger G, et al
    TTF-1 status in early-stage lung adenocarcinoma is an independent predictor of relapse and survival superior to tumor grading.
    Eur J Cancer. 2024;197:113474.
    PubMed     Abstract available


  17. WATANABE S, Furuya N, Nakamura A, Shiihara J, et al
    A phase II study of atezolizumab with bevacizumab, carboplatin, and paclitaxel for patients with EGFR-mutated NSCLC after TKI treatment failure (NEJ043 study).
    Eur J Cancer. 2024;197:113469.
    PubMed     Abstract available


    December 2023
  18. STEMMER A, Margalit O, Serpas V, Strauss G, et al
    Immunotherapy in mismatch repair-deficient metastatic colorectal cancer - Outcome and novel predictive markers.
    Eur J Cancer. 2023;198:113495.
    PubMed     Abstract available


  19. REMON J, Lopez A, Planchard D, Besse B, et al
    Are we ready to escalate or de-escalate immune treatment strategies in NSCLC based on liquid biopsy data?
    Eur J Cancer. 2023;195:113369.
    PubMed    


  20. BOSI C, Bartha A, Galbardi B, Notini G, et al
    Pan-cancer analysis of antibody-drug conjugate targets and putative predictors of treatment response.
    Eur J Cancer. 2023;195:113379.
    PubMed     Abstract available


    November 2023
  21. WENG PC, Huang YL, Cheng CY
    Osimertinib-induced urticarial vasculitis in a patient with lung cancer: A rare cutaneous toxicity.
    Eur J Cancer. 2023;196:113432.
    PubMed    


  22. FAKIH M, Wang C, Sandhu J, Ye J, et al
    Immunotherapy response in microsatellite stable metastatic colorectal cancer is influenced by site of metastases.
    Eur J Cancer. 2023;196:113437.
    PubMed     Abstract available


  23. RATAIN MJ, Strohbehn GW
    Combining atezolizumab 1200 mg with bevacizumab 15 mg/kg: based on science or just revenues?
    Eur J Cancer. 2023;194:113349.
    PubMed     Abstract available


    October 2023
  24. NUCCIO A, Viscardi G, Salomone F, Servetto A, et al
    Systematic review and meta-analysis of immune checkpoint inhibitors as single agent or in combination with chemotherapy in early-stage non-small cell lung cancer: Impact of clinicopathological factors and indirect comparison between treatment strategi
    Eur J Cancer. 2023;195:113404.
    PubMed     Abstract available


  25. YAMADA T, Goto Y, Tanaka H, Kimura H, et al
    A phase 2 trial of durvalumab treatment following radiation monotherapy in patients with non-small cell lung cancer ineligible for stage III chemoradiotherapy: The SPIRAL-RT study.
    Eur J Cancer. 2023;195:113373.
    PubMed     Abstract available


  26. LEARY A, Oaknin A, Trigo JM, Moreno V, et al
    Pooled Safety Analysis of Single-Agent Lurbinectedin in Patients With Advanced Solid Tumours.
    Eur J Cancer. 2023;192:113259.
    PubMed     Abstract available


    September 2023
  27. BRUGIERES L, Cozic N, Houot R, Rigaud C, et al
    Efficacy and safety of crizotinib in ALK-positive systemic anaplastic large-cell lymphoma in children, adolescents, and adult patients: results of the French AcSe-crizotinib trial.
    Eur J Cancer. 2023;191:112984.
    PubMed     Abstract available


  28. SHA S, Chen LJ, Brenner H, Schottker B, et al
    Associations of 25-hydroxyvitamin D status and vitamin D supplementation use with mortality due to 18 frequent cancer types in the UK Biobank cohort.
    Eur J Cancer. 2023;191:113241.
    PubMed     Abstract available


    August 2023
  29. YANG CY, Shih JY, Liao WY, Ho CC, et al
    Upfront liquid next-generation sequencing in treatment-naive advanced non-small cell lung cancer patients: A prospective randomised study in the Taiwanese health system.
    Eur J Cancer. 2023;193:113310.
    PubMed     Abstract available


    July 2023
  30. DUMOULIN DW, Aarts MJ, De Ruysscher D, Aerts JGJV, et al
    Trends in the epidemiology of small-cell lung cancer: a Dutch nationwide population-based study over 1989-2020.
    Eur J Cancer. 2023;191:112985.
    PubMed     Abstract available


  31. NORMANNO N, De Luca A, Abate RE, Morabito A, et al
    Current practice of genomic profiling of patients with advanced solid tumours in Italy: the Italian Register of Actionable Mutations (RATIONAL) study.
    Eur J Cancer. 2023;187:174-184.
    PubMed     Abstract available


    June 2023
  32. JONGBLOED M, Bartolomeo V, Steens M, Dursun S, et al
    Treatment outcome of patients with synchronous oligometastatic non-small cell lung cancer in the immunotherapy era: Analysis of a real-life intention-to-treat population.
    Eur J Cancer. 2023;190:112947.
    PubMed     Abstract available


  33. XIONG A, Li W, Li X, Fan Y, et al
    Efficacy and safety of KN046, a novel bispecific antibody against PD-L1 and CTLA-4, in patients with non-small cell lung cancer who failed platinum-based chemotherapy: a phase II study.
    Eur J Cancer. 2023;190:112936.
    PubMed     Abstract available


    May 2023
  34. HAN R, Guo H, Shi J, Wang H, et al
    Tumour microenvironment changes after osimertinib treatment resistance in non-small cell lung cancer.
    Eur J Cancer. 2023;189:112919.
    PubMed     Abstract available


  35. CORTIULA F, De Ruysscher D, Steens M, Wijsman R, et al
    Adjuvant durvalumab after concurrent chemoradiotherapy for patients with unresectable stage III NSCLC harbouring uncommon genomic alterations.
    Eur J Cancer. 2023;184:172-178.
    PubMed     Abstract available


  36. XIN Z, You L, Na F, Li J, et al
    Immunogenetic variations predict immune-related adverse events for PD-1/PD-L1 inhibitors.
    Eur J Cancer. 2023;184:124-136.
    PubMed     Abstract available


    April 2023
  37. XU Y, Yan J, Zhou C, Wu L, et al
    Genomic characterisation of de novo EGFR copy number gain and its impact on the efficacy of first-line EGFR-tyrosine kinase inhibitors for EGFR mutated non-small cell lung cancer.
    Eur J Cancer. 2023;188:81-89.
    PubMed     Abstract available


  38. WOLF J, Garon EB, Groen HJM, Tan DSW, et al
    Patient-reported outcomes in capmatinib-treated patients with METex14-mutated advanced NSCLC: Results from the GEOMETRY mono-1 study.
    Eur J Cancer. 2023;183:98-108.
    PubMed     Abstract available


    March 2023
  39. SAITO R, Sugawara S, Ko R, Azuma K, et al
    Phase 2 study of osimertinib in combination with platinum and pemetrexed in patients with previously untreated EGFR-mutated advanced non-squamous non-small cell lung cancer: The OPAL Study.
    Eur J Cancer. 2023;185:83-93.
    PubMed     Abstract available


  40. PRETE AA, Manca P, Messina M, Formica V, et al
    Extensive molecular profiling of squamous cell anal carcinoma in a phase 2 trial population: Translational analyses of the "CARACAS" study.
    Eur J Cancer. 2023;182:87-97.
    PubMed     Abstract available


  41. NEYT M, Devos C, Thiry N, Silversmit G, et al
    Belgian observational survival data (incidence years 2004-2017) and expenditure for innovative oncology drugs in twelve cancer indications.
    Eur J Cancer. 2023;182:23-37.
    PubMed     Abstract available


    February 2023
  42. BACKMAN M, Strell C, Lindberg A, Mattsson JSM, et al
    Spatial immunophenotyping of the tumour microenvironment in non-small cell lung cancer.
    Eur J Cancer. 2023;185:40-52.
    PubMed     Abstract available


  43. ROULLEAUX DUGAGE M, Albarran-Artahona V, Laguna JC, Chaput N, et al
    Biomarkers of response to immunotherapy in early stage non-small cell lung cancer.
    Eur J Cancer. 2023;184:179-196.
    PubMed     Abstract available


  44. NAKAMURA A, Yamaguchi O, Mori K, Miura K, et al
    Multicentre real-world data of ramucirumab plus docetaxel after combined platinum-based chemotherapy with programmed death-1 blockade in advanced non-small cell lung cancer: NEJ051 (REACTIVE study).
    Eur J Cancer. 2023;184:62-72.
    PubMed     Abstract available


  45. TOHIDINEZHAD F, Bontempi D, Zhang Z, Dingemans AM, et al
    Computed tomography-based radiomics for the differential diagnosis of pneumonitis in stage IV non-small cell lung cancer patients treated with immune checkpoint inhibitors.
    Eur J Cancer. 2023;183:142-151.
    PubMed     Abstract available


    January 2023
  46. BYLICKI O, Tomasini P, Radj G, Guisier F, et al
    Atezolizumab with or without bevacizumab and platinum-pemetrexed in patients with stage IIIB/IV non-squamous non-small cell lung cancer with EGFR mutation, ALK rearrangement or ROS1 fusion progressing after targeted therapies: A multicentre phase II o
    Eur J Cancer. 2023;183:38-48.
    PubMed     Abstract available


  47. RECK M, Ciuleanu TE, Cobo M, Schenker M, et al
    First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in metastatic non-small cell lung cancer: CheckMate 9LA 2-year patient-reported outcomes.
    Eur J Cancer. 2023;183:174-187.
    PubMed     Abstract available


  48. ROUSSEAU A, Tagliamento M, Auclin E, Aldea M, et al
    Clinical outcomes by infusion timing of immune checkpoint inhibitors in patients with advanced non-small cell lung cancer.
    Eur J Cancer. 2023;182:107-114.
    PubMed     Abstract available


  49. ANTOUN S, Lanoy E, Ammari S, Farhane S, et al
    Protective effect of obesity on survival in cancers treated with immunotherapy vanishes when controlling for type of cancer, weight loss and reduced skeletal muscle.
    Eur J Cancer. 2023;178:49-59.
    PubMed     Abstract available


  50. RIEDEL R, Fassunke J, Tumbrink HL, Scheel AH, et al
    Resistance to MET inhibition in MET-dependent NSCLC and therapeutic activity after switching from type I to type II MET inhibitors.
    Eur J Cancer. 2023;179:124-135.
    PubMed     Abstract available


  51. VELEV M, Baroudjian B, Pruvost R, De Martin E, et al
    Immune-related generalised oedema - A new category of adverse events with immune checkpoint inhibitors.
    Eur J Cancer. 2023;179:28-47.
    PubMed     Abstract available


  52. IMAJI M, Fujimoto D, Sato Y, Sakata Y, et al
    Safety and efficacy of osimertinib rechallenge or continuation after pneumonitis: A multicentre retrospective cohort study.
    Eur J Cancer. 2023;179:15-24.
    PubMed     Abstract available


    December 2022
  53. HONDELINK LM, Ernst SM, Atmodimedjo P, Cohen D, et al
    Prevalence, clinical and molecular characteristics of early stage EGFR-mutated lung cancer in a real-life West-European cohort: Implications for adjuvant therapy.
    Eur J Cancer. 2022;181:53-61.
    PubMed     Abstract available


  54. SHE Y, Li S, Deng J, Ren Y, et al
    Clinicopathologic characteristics and prognostic impact of atypical EGFR mutations in completely resected lung adenocarcinoma.
    Eur J Cancer. 2022;177:53-62.
    PubMed     Abstract available


    November 2022
  55. WAISSENGRIN B, Leshem Y, Taya M, Meiri D, et al
    The use of medical cannabis concomitantly with immune checkpoint inhibitors in non-small cell lung cancer: A sigh of relief?
    Eur J Cancer. 2022;180:52-61.
    PubMed     Abstract available


  56. IMAI S, Mitsuboshi S, Hori S, Suzuki S, et al
    Increased risk of Lambert-Eaton myasthenic syndrome (LEMS) in small-cell lung cancer patients treated with immune checkpoint inhibitor.
    Eur J Cancer. 2022;180:1-3.
    PubMed    


  57. MOROSI C, Bergamaschi L, Livellara V, Hassan V, et al
    Relapsing pediatric non-rhabdomyosarcoma soft tissue sarcomas: The impact of routine imaging surveillance on early detection and post-relapse survival.
    Eur J Cancer. 2022;175:274-281.
    PubMed     Abstract available


    October 2022
  58. SAW SPL, Ng WP, Zhou S, Lai GGY, et al
    PD-L1 score as a prognostic biomarker in asian early-stage epidermal growth factor receptor-mutated lung cancer.
    Eur J Cancer. 2022;178:139-149.
    PubMed     Abstract available


  59. TABBO F, Muscarella LA, Gobbini E, Trombetta D, et al
    Detection of ALK fusion variants by RNA-based NGS and clinical outcome correlation in NSCLC patients treated with ALK-TKI sequences.
    Eur J Cancer. 2022;174:200-211.
    PubMed     Abstract available


  60. BASAK EA, Vermeer NS, de Joode K, Hurkmans DP, et al
    Associations between patient and disease characteristics and severe adverse events during immune checkpoint inhibitor treatment: An observational study.
    Eur J Cancer. 2022;174:113-120.
    PubMed     Abstract available


  61. WANG W, Lin G, Hao Y, Guan Y, et al
    Treatment outcomes and prognosis of immune checkpoint inhibitors therapy in patients with advanced thymic carcinoma: A multicentre retrospective study.
    Eur J Cancer. 2022;174:21-30.
    PubMed     Abstract available


    September 2022
  62. RACOVITA M, Wheeler E, Wait S, Albreht T, et al
    The need for a comprehensive and integrated approach to lung cancer policy in Europe.
    Eur J Cancer. 2022;175:54-59.
    PubMed     Abstract available


  63. ABELE M, Bajciova V, Wright F, Behjati S, et al
    Primary lung carcinoma in children and adolescents: An analysis of the European Cooperative Study Group on Paediatric Rare Tumours (EXPeRT).
    Eur J Cancer. 2022;175:19-30.
    PubMed     Abstract available


    August 2022
  64. FOY JP, Karabajakian A, Ortiz-Cuaran S, Boussageon M, et al
    Immunologically active phenotype by gene expression profiling is associated with clinical benefit from PD-1/PD-L1 inhibitors in real-world head and neck and lung cancer patients.
    Eur J Cancer. 2022 Aug 26. pii: S0959-8049(22)00385.
    PubMed     Abstract available


  65. KOH J, Kim S, Woo YD, Song SG, et al
    TCF1(+)PD-1(+) tumour-infiltrating lymphocytes predict a favorable response and prolonged survival after immune checkpoint inhibitor therapy for non-small-cell lung cancer.
    Eur J Cancer. 2022;174:10-20.
    PubMed     Abstract available


  66. O'SULLIVAN H, d'Arienzo PD, Yousaf N, Cui W, et al
    Response to letter entitled: Re: 'Inadequacy of PCR genotyping in advanced non-small cell lung cancer: EGFR L747_A755delinsSS exon 19 deletion is not detected by the real-time PCR Idylla(TM) EGFR mutation test but is detected by ctDNA NGS and responds
    Eur J Cancer. 2022 Aug 7. pii: S0959-8049(22)00391.
    PubMed    


  67. MA Y, Zhao H, Xue J, Liu L, et al
    First-in-human phase I study of TQ-B3139 (CT-711) in advanced non-small cell lung cancer patients with ALK and ROS1 rearrangements.
    Eur J Cancer. 2022;173:238-249.
    PubMed     Abstract available


  68. BENNETT P, Finall A, Medeiros F, Gerrard G, et al
    Re: Inadequacy of PCR genotyping in advanced non-small cell lung cancer: EGFR L747_A755delinsSS Exon 19 deletion is not detected by the real-time PCR IdyllaTM EGFR mutation test but is detected by ctDNA NGS and responds to osimertinib.
    Eur J Cancer. 2022 Aug 4. pii: S0959-8049(22)00390.
    PubMed    


  69. ESPENEL S, Chargari C, Blanchard P, Bockel S, et al
    Practice changing data and emerging concepts from recent radiation therapy randomised clinical trials.
    Eur J Cancer. 2022;171:242-258.
    PubMed     Abstract available


    July 2022
  70. DUMOULIN DW, Cantini L, Cornelissen R, Vink M, et al
    Lurbinectedin shows clinical activity and immune-modulatory functions in patients with pre-treated small cell lung cancer and malignant pleural mesothelioma.
    Eur J Cancer. 2022;172:357-366.
    PubMed     Abstract available


  71. TAN DSW, Kim SW, Ponce Aix S, Sequist LV, et al
    Nazartinib for treatment-naive EGFR-mutant non-small cell lung cancer: Results of a phase 2, single-arm, open-label study.
    Eur J Cancer. 2022;172:276-286.
    PubMed     Abstract available


  72. WANG C, Hu Q, Sun Y, Yu F, et al
    Complete pathological remission after neoadjuvant ensartinib in patients with locally advanced lung adenocarcinoma and with CTLC-ALK and ALK-DHX8 rearrangements.
    Eur J Cancer. 2022;169:131-134.
    PubMed    


    June 2022
  73. TAKADA K, Buti S, Bersanelli M, Shimokawa M, et al
    Antibiotic-dependent effect of probiotics in patients with non-small cell lung cancer treated with PD-1 checkpoint blockade.
    Eur J Cancer. 2022;172:199-208.
    PubMed     Abstract available


  74. PRIOU S, Lame G, Zalcman G, Wislez M, et al
    Influence of the SARS-CoV-2 outbreak on management and prognosis of new lung cancer cases, a retrospective multicentre real-life cohort study.
    Eur J Cancer. 2022;173:33-40.
    PubMed     Abstract available


  75. ABED A, Law N, Calapre L, Lo J, et al
    Human leucocyte antigen genotype association with the development of immune-related adverse events in patients with non-small cell lung cancer treated with single agent immunotherapy.
    Eur J Cancer. 2022;172:98-106.
    PubMed     Abstract available


  76. ROSELLINI P, Amintas S, Caumont C, Veillon R, et al
    Clinical impact of STK11 mutation in advanced-stage non-small cell lung cancer.
    Eur J Cancer. 2022;172:85-95.
    PubMed     Abstract available


  77. BAUM P, Winter H, Eichhorn ME, Roesch RM, et al
    Trends in age- and sex-specific lung cancer mortality in Europe and Northern America: Analysis of vital registration data from the WHO Mortality Database between 2000 and 2017.
    Eur J Cancer. 2022 Jun 15. pii: S0959-8049(22)00289.
    PubMed     Abstract available


  78. VAN BERGE HENEGOUWEN JM, Jebbink M, Hoes LR, van der Wijngaart H, et al
    Trastuzumab and pertuzumab combination therapy for advanced pre-treated HER2 exon 20-mutated non-small cell lung cancer.
    Eur J Cancer. 2022;171:114-123.
    PubMed     Abstract available


  79. BRYANT AK, Sankar K, Zhao L, Strohbehn GW, et al
    De-escalating adjuvant durvalumab treatment duration in stage III non-small cell lung cancer.
    Eur J Cancer. 2022;171:55-63.
    PubMed     Abstract available


  80. CUI W, Milner-Watts C, O'Sullivan H, Lyons H, et al
    Up-front cell-free DNA next generation sequencing improves target identification in UK first line advanced non-small cell lung cancer (NSCLC) patients.
    Eur J Cancer. 2022;171:44-54.
    PubMed     Abstract available


    May 2022
  81. HAN Y, Lee T, He Y, Raman R, et al
    The regulation of CD73 in non-small cell lung cancer.
    Eur J Cancer. 2022;170:91-102.
    PubMed     Abstract available


  82. CHRISTOPOULOS P, Kluck K, Kirchner M, Luders H, et al
    The impact of TP53 co-mutations and immunologic microenvironment on outcome of lung cancer with EGFR exon 20 insertions.
    Eur J Cancer. 2022;170:106-118.
    PubMed     Abstract available


  83. CHOI S, Cho SI, Ma M, Park S, et al
    Artificial intelligence-powered programmed death ligand 1 analyser reduces interobserver variation in tumour proportion score for non-small cell lung cancer with better prediction of immunotherapy response.
    Eur J Cancer. 2022;170:17-26.
    PubMed     Abstract available


  84. ORTIZ-CUARAN S, Swalduz A, Foy JP, Marteau S, et al
    Epithelial-to-mesenchymal transition promotes immune escape by inducing CD70 in non-small cell lung cancer.
    Eur J Cancer. 2022;169:106-122.
    PubMed     Abstract available


  85. BANNA GL, Signori A, Curioni-Fontecedro A, Cortellini A, et al
    Systemic therapy for pre-treated malignant mesothelioma: A systematic review, meta-analysis and network meta-analysis of randomised controlled trials.
    Eur J Cancer. 2022;166:287-299.
    PubMed     Abstract available


    April 2022
  86. PARK S, Noh JM, Choi YL, Chi SA, et al
    Durvalumab with chemoradiotherapy for limited-stage small-cell lung cancer.
    Eur J Cancer. 2022;169:42-53.
    PubMed     Abstract available


  87. TEN BERGE DMHJ, Aarts MJ, Groen HJM, Aerts JGJV, et al
    A population-based study describing characteristics, survival and the effect of TKI treatment on patients with EGFR mutated stage IV NSCLC in the Netherlands.
    Eur J Cancer. 2022;165:195-204.
    PubMed     Abstract available


  88. PAN Y, Zeng Y, Peng Y, Liu X, et al
    Dramatic response to brigatinib in a lung adenocarcinoma patient harboring EML4-ALK fusion and a G1202R de novo gene mutation.
    Eur J Cancer. 2022;165:154-156.
    PubMed    


  89. SANTUCCI C, Patel L, Malvezzi M, Wojtyla C, et al
    Persisting cancer mortality gap between western and eastern Europe.
    Eur J Cancer. 2022;165:1-12.
    PubMed     Abstract available


    March 2022
  90. DE RUYSSCHER D, Remon J, Hendriks LEL
    Who benefits from consolidation durvalumab in stage III non-small cell lung cancer?
    Eur J Cancer. 2022 Mar 17. pii: S0959-8049(22)00107.
    PubMed    


  91. RIUDAVETS M, Auclin E, Mosteiro M, Dempsey N, et al
    Durvalumab consolidation in patients with unresectable stage III non-small cell lung cancer with driver genomic alterations.
    Eur J Cancer. 2022 Mar 17. pii: S0959-8049(22)00106.
    PubMed     Abstract available


  92. REMON J, Lacas B, Herbst R, Reck M, et al
    ANtiangiogenic Second-line Lung cancer Meta-Analysis on individual patient data in non-small cell lung cancer: ANSELMA.
    Eur J Cancer. 2022;166:112-125.
    PubMed     Abstract available


  93. BALDACCI S, Besse B, Avrillon V, Mennecier B, et al
    Lorlatinib for advanced anaplastic lymphoma kinase-positive non-small cell lung cancer: Results of the IFCT-1803 LORLATU cohort.
    Eur J Cancer. 2022;166:51-59.
    PubMed     Abstract available


  94. FUJIMOTO D, Akamatsu H, Morimoto T, Wakuda K, et al
    Histologic transformation of epidermal growth factor receptor-mutated lung cancer.
    Eur J Cancer. 2022;166:41-50.
    PubMed     Abstract available


  95. O'SULLIVAN H, d'Arienzo PD, Yousaf N, Cui W, et al
    Inadequacy of PCR genotyping in advanced non-small cell lung cancer: EGFR L747_A755delinsSS exon 19 deletion is not detected by the real-time PCR Idylla EGFR mutation test but is detected by ctDNA next generation sequencing and responds to osimertinib
    Eur J Cancer. 2022;166:38-40.
    PubMed    


  96. NAHM SH, Heywood R, Callaghan S, Serra-Bellver P, et al
    Patient and treatment characteristics of emergency presentations due to immune-mediated toxicities.
    Eur J Cancer. 2022;164:62-69.
    PubMed     Abstract available


  97. SCULCO M, La Vecchia M, Aspesi A, Pinton G, et al
    Malignant pleural mesothelioma: Germline variants in DNA repair genes may steer tailored treatment.
    Eur J Cancer. 2022;163:44-54.
    PubMed     Abstract available


    February 2022
  98. BACIARELLO G, Ozguroglu M, Mundle S, Leitz G, et al
    Impact of abiraterone acetate plus prednisone in patients with castration-sensitive prostate cancer and visceral metastases over four years of follow-up: A post-hoc exploratory analysis of the LATITUDE study.
    Eur J Cancer. 2022;162:56-64.
    PubMed     Abstract available


    January 2022
  99. STEINDL A, Brunner TJ, Heimbach K, Schweighart K, et al
    Changing characteristics, treatment approaches and survival of patients with brain metastasis: data from six thousand and thirty-one individuals over an observation period of 30 years.
    Eur J Cancer. 2022;162:170-181.
    PubMed     Abstract available


    December 2021
  100. IWAMA E, Zenke Y, Sugawara S, Daga H, et al
    Trastuzumab emtansine for patients with non-small cell lung cancer positive for human epidermal growth factor receptor 2 exon-20 insertion mutations.
    Eur J Cancer. 2021;162:99-106.
    PubMed     Abstract available


  101. SHIRASAWA M, Yoshida T, Imabayashi T, Okuma K, et al
    Baseline PD-L1 expression and tumour-infiltrated lymphocyte status predict the efficacy of durvalumab consolidation therapy after chemoradiotherapy in unresectable locally advanced patients with non-small-cell lung cancer.
    Eur J Cancer. 2021;162:1-10.
    PubMed     Abstract available


  102. SUZUKI S, Haratani K, Hayashi H, Chiba Y, et al
    Association of tumour burden with the efficacy of programmed cell death-1/programmed cell death ligand-1 inhibitors for treatment-naive advanced non-small-cell lung cancer.
    Eur J Cancer. 2021;161:44-54.
    PubMed     Abstract available


  103. JIANG F, Lin JK, Xiang Y, Xu ZF, et al
    The impact of pulmonary metastases on therapeutic response and prognosis in malignant gestational trophoblastic neoplasia patients: a retrospective cohort study.
    Eur J Cancer. 2021 Dec 13. pii: S0959-8049(21)01212.
    PubMed     Abstract available


  104. HO CSL, Tuns AI, Schildhaus HU, Wiesweg M, et al
    HER2 mediates clinical resistance to the KRAS(G12C) inhibitor sotorasib, which is overcome by co-targeting SHP2.
    Eur J Cancer. 2021;159:16-23.
    PubMed     Abstract available


    November 2021
  105. MIZUGAKI H, Oizumi S, Fujita Y, Harada T, et al
    Pharmacokinetic and pharmacogenomic analysis of low-dose afatinib treatment in elderly patients with EGFR mutation-positive non-small cell lung cancer.
    Eur J Cancer. 2021 Nov 30. pii: S0959-8049(21)01182.
    PubMed     Abstract available


  106. HOPKINS AM, Abuhelwa AY, McKinnon RA, Logan JM, et al
    Smoking and immunotherapy efficacy in lung cancer by PDL1 subgroups: An individual participant data meta-analysis of atezolizumab clinical trials: Smoking and immunotherapy efficacy in lung cancer.
    Eur J Cancer. 2021 Nov 30. pii: S0959-8049(21)01178.
    PubMed    


  107. PERALTA-ARRIETA I, Trejo-Villegas OA, Armas-Lopez L, Ceja-Rangel HA, et al
    Failure to EGFR-TKI-based therapy and tumoural progression are promoted by MEOX2/GLI1-mediated epigenetic regulation of EGFR in the human lung cancer.
    Eur J Cancer. 2021 Nov 26. pii: S0959-8049(21)01190.
    PubMed     Abstract available


  108. VASSELLA E, Kashani E, Zens P, Kundig A, et al
    Mutational profiles of primary pulmonary adenocarcinoma and paired brain metastases disclose the importance of KRAS mutations.
    Eur J Cancer. 2021;159:227-236.
    PubMed     Abstract available


  109. MAJEM M, Sullivan I, Viteri S, Lopez-Vivanco G, et al
    First-line osimertinib in patients with epidermal growth factor receptor-mutant non-small-cell lung cancer and with a coexisting low allelic fraction of Thr790Met.
    Eur J Cancer. 2021;159:174-181.
    PubMed     Abstract available


  110. LEE YP, Jeong BH, Eun Y, Kang CI, et al
    Extrapulmonary tuberculosis in patients with RET fusion-positive non-small cell lung cancer treated with pralsetinib: A Korean single-centre compassionate use experience.
    Eur J Cancer. 2021;159:167-173.
    PubMed     Abstract available


  111. SAKATA Y, Sakata S, Oya Y, Tamiya M, et al
    Osimertinib as first-line treatment for advanced epidermal growth factor receptor mutation-positive non-small-cell lung cancer in a real-world setting (OSI-FACT).
    Eur J Cancer. 2021;159:144-153.
    PubMed     Abstract available


  112. RUSTE V, Goldschmidt V, Laparra A, Messayke S, et al
    The determinants of very severe immune-related adverse events associated with immune checkpoint inhibitors: A prospective study of the French REISAMIC registry.
    Eur J Cancer. 2021;158:217-224.
    PubMed     Abstract available


    September 2021
  113. DI FEDERICO A, De Giglio A, Parisi C, Gelsomino F, et al
    STK11/LKB1 and KEAP1 mutations in non-small cell lung cancer: Prognostic rather than predictive?
    Eur J Cancer. 2021;157:108-113.
    PubMed     Abstract available


  114. LEONETTI A, Giudice GC, Perrone F, Tiseo M, et al
    Letter comments on: The effects of antibiotics on the efficacy of immune-checkpoint inhibitors in non-small cell lung cancer patients differ according to PD-L1 expression.
    Eur J Cancer. 2021 Sep 6. pii: S0959-8049(21)00517.
    PubMed    


  115. SUTCUOGLU O, Ozdemir N, Yazici O
    Re: Post-progression outcomes of NSCLC patients with PD-L1 expression >/=50% receiving first-line single-agent pembrolizumab in a large multicentre real-world study.
    Eur J Cancer. 2021;155:294-295.
    PubMed    


    August 2021
  116. OCHI N, Ichihara E, Takigawa N, Harada D, et al
    Response to letter re: The effects of antibiotics on the efficacy of immune-checkpoint inhibitors in non-small cell lung cancer patients differ according to PD-L1 expression.
    Eur J Cancer. 2021 Aug 31. pii: S0959-8049(21)00518.
    PubMed    


  117. FAEHLING M, Fallscheer S, Kramberg S, Strater J, et al
    Prospective trial of immuno(chemo)therapy before resection, definitive chemoradiotherapy or palliative therapy in patients with locally advanced or oligometastatic non-small cell lung cancer without a primary curative option.
    Eur J Cancer. 2021;156:175-186.
    PubMed     Abstract available


  118. CORTELLINI A, Bersanelli M, Pinato DJ, Buti S, et al
    Response to letter entitled: Re: Predictive ability of a drug-based score in advanced non-small cell lung cancer patients receiving first-line immunotherapy.
    Eur J Cancer. 2021 Aug 12. pii: S0959-8049(21)00459.
    PubMed    


  119. LIN YT, Chiang CL, Hung JY, Lee MH, et al
    Resistance profiles of anaplastic lymphoma kinase tyrosine kinase inhibitors in advanced non-small-cell lung cancer: a multicenter study using targeted next-generation sequencing.
    Eur J Cancer. 2021;156:1-11.
    PubMed     Abstract available


  120. TAKADA K, Takamori S, Miura N, Shikada Y, et al
    Re: Predictive ability of a drug-based score in patients with advanced non-small-cell lung cancer receiving first-line immunotherapy.
    Eur J Cancer. 2021 Aug 6. pii: S0959-8049(21)00458.
    PubMed    


    July 2021
  121. DISSELHORST MJ, de Vries R, Quispel-Janssen J, Wolf-Lansdorf M, et al
    Nose in malignant mesothelioma-Prediction of response to immune checkpoint inhibitor treatment.
    Eur J Cancer. 2021;152:60-67.
    PubMed     Abstract available


  122. MEZQUITA L, Preeshagul I, Auclin E, Saravia D, et al
    Predicting immunotherapy outcomes under therapy in patients with advanced NSCLC using dNLR and its early dynamics.
    Eur J Cancer. 2021;151:211-220.
    PubMed     Abstract available


  123. ZHU Y, Tian J, Peng X, Wang X, et al
    A genetic variant conferred high expression of CAV2 promotes pancreatic cancer progression and associates with poor prognosis.
    Eur J Cancer. 2021;151:94-105.
    PubMed     Abstract available


  124. GAN CL, Stukalin I, Meyers DE, Dudani S, et al
    Outcomes of patients with solid tumour malignancies treated with first-line immuno-oncology agents who do not meet eligibility criteria for clinical trials.
    Eur J Cancer. 2021;151:115-125.
    PubMed     Abstract available


    June 2021
  125. AHN BC, So JW, Synn CB, Kim TH, et al
    Clinical decision support algorithm based on machine learning to assess the clinical response to anti-programmed death-1 therapy in patients with non-small-cell lung cancer.
    Eur J Cancer. 2021;153:179-189.
    PubMed     Abstract available


  126. CANTINI L, Pecci F, Dammeijer F, Aerts JGJV, et al
    Re: Comments on 'High-intensity statins are associated with improved clinical activity of programmed cell death protein 1 inhibitors in malignant pleural mesothelioma and advanced non-small cell lung cancer patients'.
    Eur J Cancer. 2021 Jun 18. pii: S0959-8049(21)00325.
    PubMed    


  127. KURRECK A, Weckwerth J, Modest DP, Striefler JK, et al
    Impact of completeness of adjuvant gemcitabine, relapse pattern, and subsequent therapy on outcome of patients with resected pancreatic ductal adenocarcinoma - A pooled analysis of CONKO-001, CONKO-005, and CONKO-006 trials.
    Eur J Cancer. 2021;150:250-259.
    PubMed     Abstract available


    May 2021
  128. HARA A, Matsuda M, Ishii A, Yoshioka T, et al
    Comments on 'High-intensity statins are associated with improved clinical activity of PD-1 inhibitors in malignant pleural mesothelioma and advanced non-small cell lung cancer patients'.
    Eur J Cancer. 2021 May 22. pii: S0959-8049(21)00256.
    PubMed    


  129. SAESEN R, Lacombe D, Huys I
    Design, organisation and impact of treatment optimisation studies in breast, lung and colorectal cancer: The experience of the European Organisation for Research and Treatment of Cancer.
    Eur J Cancer. 2021;151:221-232.
    PubMed     Abstract available


  130. BOGATYROVA O, Mattsson JSM, Ross EM, Sanderson MP, et al
    FGFR1 overexpression in non-small cell lung cancer is mediated by genetic and epigenetic mechanisms and is a determinant of FGFR1 inhibitor response.
    Eur J Cancer. 2021;151:136-149.
    PubMed     Abstract available


  131. IKEDA S, Kato T, Kenmotsu H, Okamoto H, et al
    Immune checkpoint inhibitor for non-small cell lung cancer with comorbid interstitial pneumonia; a prudent stance required.
    Eur J Cancer. 2021 May 4. pii: S0959-8049(21)00217.
    PubMed    


  132. DUCHEMANN B, Pluvy J, Crestani B, Zalcman G, et al
    Immune checkpoint inhibitors for patients with lung cancer and IPF: Specific clinical trials needed.
    Eur J Cancer. 2021 May 4. pii: S0959-8049(21)00219.
    PubMed    


  133. ROGADO J, Gullon P, Obispo B, Serrano G, et al
    Prolonged SARS-CoV-2 viral shedding in patients with solid tumours and associated factors.
    Eur J Cancer. 2021;148:58-60.
    PubMed    


  134. WIESWEG M, Preuss C, Roeper J, Metzenmacher M, et al
    BRAF mutations and BRAF mutation functional class have no negative impact on the clinical outcome of advanced NSCLC and associate with susceptibility to immunotherapy.
    Eur J Cancer. 2021;149:211-221.
    PubMed     Abstract available


  135. GHISONI E, Wicky A, Bouchaab H, Imbimbo M, et al
    Late-onset and long-lasting immune-related adverse events from immune checkpoint-inhibitors: An overlooked aspect in immunotherapy.
    Eur J Cancer. 2021;149:153-164.
    PubMed     Abstract available


  136. PRELAJ A, Bottiglieri A, Proto C, Lo Russo G, et al
    Poziotinib for EGFR and HER2 exon 20 insertion mutation in advanced NSCLC: Results from the expanded access program.
    Eur J Cancer. 2021;149:235-248.
    PubMed     Abstract available


  137. KHORRAMI M, Bera K, Thawani R, Rajiah P, et al
    Distinguishing granulomas from adenocarcinomas by integrating stable and discriminating radiomic features on non-contrast computed tomography scans.
    Eur J Cancer. 2021;148:146-158.
    PubMed     Abstract available


  138. CORTELLINI A, Cannita K, Tiseo M, Cortinovis DL, et al
    Post-progression outcomes of NSCLC patients with PD-L1 expression >/= 50% receiving first-line single-agent pembrolizumab in a large multicentre real-world study.
    Eur J Cancer. 2021;148:24-35.
    PubMed     Abstract available


    April 2021
  139. BUTI S, Bersanelli M, Perrone F, Bracarda S, et al
    Predictive ability of a drug-based score in patients with advanced non-small-cell lung cancer receiving first-line immunotherapy.
    Eur J Cancer. 2021;150:224-231.
    PubMed     Abstract available


  140. DALL'OLIO FG, Calabro D, Conci N, Argalia G, et al
    Baseline total metabolic tumour volume on 2-deoxy-2-[18F]fluoro-d-glucose positron emission tomography-computed tomography as a promising biomarker in patients with advanced non-small cell lung cancer treated with first-line pembrolizumab.
    Eur J Cancer. 2021;150:99-107.
    PubMed     Abstract available


  141. FUJIMOTO D, Miura S, Yoshimura K, Wakuda K, et al
    Pembrolizumab plus chemotherapy-induced pneumonitis in chemo-naive patients with non-squamous non-small cell lung cancer: A multicentre, retrospective cohort study.
    Eur J Cancer. 2021;150:63-72.
    PubMed     Abstract available


  142. ZHENG MM, Tu HY, Yang JJ, Zhang XC, et al
    Clinical outcomes of non-small cell lung cancer patients with leptomeningeal metastases after immune checkpoint inhibitor treatments.
    Eur J Cancer. 2021;150:23-30.
    PubMed     Abstract available


  143. JACOBS F, Carnio S, De Stefanis P, Luciano A, et al
    Pericarditis during chemoimmunotherapy for non-small cell lung cancer: an adverse event to prevent and recognise.
    Eur J Cancer. 2021;149:114-116.
    PubMed    


  144. OCHI N, Ichihara E, Takigawa N, Harada D, et al
    The effects of antibiotics on the efficacy of immune checkpoint inhibitors in patients with non-small-cell lung cancer differ based on PD-L1 expression.
    Eur J Cancer. 2021;149:73-81.
    PubMed     Abstract available


  145. PROVENCIO M, Serna-Blasco R, Franco F, Calvo V, et al
    Analysis of circulating tumour DNA to identify patients with epidermal growth factor receptor-positive non-small cell lung cancer who might benefit from sequential tyrosine kinase inhibitor treatment.
    Eur J Cancer. 2021;149:61-72.
    PubMed     Abstract available


  146. TANAKA K, Asahina H, Kishimoto J, Miyata Y, et al
    Osimertinib versus osimertinib plus chemotherapy for non-small cell lung cancer with EGFR (T790M)-associated resistance to initial EGFR inhibitor treatment: An open-label, randomised phase 2 clinical trial.
    Eur J Cancer. 2021;149:14-22.
    PubMed     Abstract available


  147. WU S, Xing X, Wang Y, Zhang X, et al
    The pathological significance of LOXL2 in pre-metastatic niche formation of HCC and its related molecular mechanism.
    Eur J Cancer. 2021;147:63-73.
    PubMed     Abstract available


  148. TAHARA M, Kiyota N, Hoff AO, Badiu C, et al
    Impact of lung metastases on overall survival in the phase 3 SELECT study of lenvatinib in patients with radioiodine-refractory differentiated thyroid cancer.
    Eur J Cancer. 2021;147:51-57.
    PubMed     Abstract available


    March 2021
  149. BASIN S, Perrin J, Michot JM, Lambotte O, et al
    Severe anti-PD1-related meningoencephalomyelitis successfully treated with anti-integrin alpha4 therapy.
    Eur J Cancer. 2021;145:230-233.
    PubMed    


  150. ANDERSSON NW, Zachariae C, Simonsen AB
    Late onset of subacute cutaneous lupus erythematosus following pembrolizumab therapy.
    Eur J Cancer. 2021;145:168-170.
    PubMed    


    February 2021
  151. MALAPELLE U, Passiglia F, Cremolini C, Reale ML, et al
    RAS as a positive predictive biomarker: focus on lung and colorectal cancer patients.
    Eur J Cancer. 2021;146:74-83.
    PubMed     Abstract available


  152. CAMASTRA G, Arcari L, Ciolina F, Danti M, et al
    Cardiac magnetic resonance imaging of transient myocardial dysfunction in a patient treated with checkpoint-targeted immunotherapy.
    Eur J Cancer. 2021;144:389-391.
    PubMed    


  153. BECKER O, Beaulaton C, Masliah-Planchon J, Servois V, et al
    Nivolumab activity in advanced refractory malignant peritoneal mesothelioma.
    Eur J Cancer. 2021;144:386-388.
    PubMed    


    January 2021
  154. BUTI S, Bersanelli M, Perrone F, Tiseo M, et al
    Effect of concomitant medications with immune-modulatory properties on the outcomes of patients with advanced cancer treated with immune checkpoint inhibitors: development and validation of a novel prognostic index.
    Eur J Cancer. 2021;142:18-28.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Lung Cancer is free of charge.